Mucopolysaccharidosis type II (MPS II, Hunter syndrome) was first described by Dr. Charles
Hunter in 1917. Since then, about one hundred years have passed and Hunter syndrome …

Most lysosomal storage diseases (LSDs) involve progressive central nervous system (CNS)
impairment, resulting from deficiency of a lysosomal enzyme. Treatment of neuronopathic …

ABSTRACT Introduction: Mucopolysaccharidosis Type II (MPS II; Hunter syndrome) is an X-
linked lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS). IDS …

Enzyme replacement therapy (ERT) has been developed for several lysosomal storage
disorders, including mucopolysaccharidosis I (MPS I), and is effective at reducing lysosomal …

Abstract Mucopolysaccharidosis Type II (MPS II) is an X-linked recessive genetic disorder
that primarily affects male patients. With an incidence of 1 in 100,000 male live births, the …

Publisher Summary This chapter discusses the structure of galactosaminoglycans (GalAGs),
their roles in biology and medicine, GalAG biosynthesis, their in vivo cellular degradation …

Abstract Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is an X-linked inherited
disorder caused by a deficiency of the enzyme iduronate-2-sulfatase (IDS), which results in …

Intrathecal enzyme replacement therapy has been proposed to treat central nervous system
(CNS) disease due to mucopolysaccharidosis type I. Our research has shown that repeated …

AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O ([C@ H] 1C
[C@@](O)(CC= 2C (O)= C3C (= O) C= 4C= CC= C (C= 4C (= O) C3= C (O) C= 21) OC) C …

Background Hunter syndrome, mucopolysaccharidosis type II (MPS II), is a X‐linked
inherited disorder caused by the deficiency of the enzyme iduronate‐2‐sulfatase (IDS) …